id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
cblr-1794	Margolis, Sara	Destined for Failure? An Analysis of the Biologics Price Competition and Innovation Act of 2009	2013	33	.pdf	application/pdf	10667	529	48	1:209]1 12-year exclusivity is unnecessary to promote innovation by brand biologic drug manufacturers and can potentially harm consumers by directing scarce research and development funding toward developing low-risk clinical data for drug products with proven mechanisms of action rather than toward new products to address unmet medical needs.182 This small market share does not pose a significant threat to reference drug manufacturers, providing them with little incentive to compete based on price.	cache/cblr-1794.pdf	txt/cblr-1794.txt